Jeremy Skillington of Poolbeg Pharma: POLB 001 achieves regulatory approval to commence human challenge clinical trial

Jeremy Skillington, CEO of Poolbeg Pharma #POLB discusses a major milestone being reached as POLB 001 achieves regulatory approval to commence its Lipopolysaccharide (LPS) human challenge clinical trial.

Key Highlights

• Clinical trial activities will formally commence on 22 July 2022

• The trial will assess the efficacy of POLB 001 in dampening the robust immune response to LPS which acts as a surrogate for the hyperinflammatory response associated with severe influenza and other diseases

• Start of the trial demonstrates significant delivery on commitment at IPO

• Initial results expected in Q4 2022 at which point the Company intends to rapidly monetise by out-licensing / partnering with pharma and biotech companies for further development of POLB 001

• Trial success would also pave the way for potential applications beyond severe influenza